Herbalife (HLF) Q2 2026 earnings summary

Executive summary

• Q2 net sales were $1,326.8M, up 5.4% year over year and 5.8% constant currency; fourth consecutive quarter of growth.

• Adjusted EBITDA was $166.6M, with a 12.6% margin; adjusted net income was $53.3M.

• Net loss attributable to shareholders was $26.3M, including a $94.6M debt-extinguishment loss from April refinancing.

• Bioniq GO and Life I/O products launched, while Pro2col and digital personalization capabilities advanced.

Financial highlights

• Q2 net sales rose 5.4% to $1,326.8M; constant-currency growth was 5.8%.

• Adjusted EBITDA was $166.6M reported and $174.4M constant currency, including a $7.6M FX headwind; margin was 12.6%, down 120 bps year over year.

• Gross profit was $1,030.5M, with a 77.7% margin, down 34 bps year over year; pricing partly offset sales mix and higher costs.

• Net loss was $26.3M, or $0.25 per diluted share; adjusted net income was $53.3M and adjusted diluted EPS was $0.51.

• First-half operating cash flow was $146.7M, up from $96.2M; net interest expense fell to $37.4M from $53.6M year over year.

Outlook and guidance

• Q3 net sales guidance: +0.5% to +4.5% reported and +1.5% to +5.5% constant currency; reported range includes a 100 bps currency headwind.

• Q3 adjusted EBITDA guidance: $160M–$180M reported and $165M–$185M constant currency.

• FY2026 net sales growth guidance: +2.5% to +5.5% reported and constant currency; ranges narrowed and midpoints raised.

• FY2026 adjusted EBITDA guidance: $670M–$690M reported and $690M–$710M constant currency.

• FY2026 CapEx guidance: $50M–$70M, with $35M–$55M in capitalized SaaS implementation costs incremental to CapEx; adjusted tax rate expected near 35%.